[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastases-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastases-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100471487","phase-2-palliative-dose-escalated-radiation-for-painful-non-spine-bone-metastases-and-painful-non-bone-metas-100471487",false,"NCT05419518","Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas","Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases","Inclusion Criteria:\n\n* Have provided signed informed consent for the trial\n* Aged ≥18 years at the time of informed consent\n* Histologic proof of malignancy\n* Radiologic or histologic evidence of bone metastases or non-bone metastases\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≥3\n* Pain Score ≥ 3\n* Life expectancy of six months or more\n* Willing and able to comply with all aspects of the protocol\n* A female participant is eligible to participate if she is not pregnant and not breastfeeding\n* Woman of childbearing potential who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.\n* A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Metastasis from a highly radiosensitive tumor (eg, lymphoma, myeloma, germ cell tumor)\n* Spinal metastasis\n* Active compression of spinal cord\u002Fcauda equina\n* Previous RT or SBRT to the same site\n* \\> 3 sites requiring radiation treatment","ALL","18 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases",[26,27],"Neoplasm Metastases","Metastases, Neoplasm",[29,30,31],"Metastase","Bone Neoplasms","Dose Fractionation, Radiation","RECRUITING","2026-05-29",{"date":35,"type":36},"2026-06-02","ACTUAL",{"date":38,"type":36},"2023-03-16",{"date":40,"type":20},"2027-04-01",{"name":42,"class":43},"Rutgers, The State University of New Jersey","OTHER",7]